Loading...
Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection
Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective of the study was to verify the effectiveness and safety of bezloto...
Na minha lista:
| Udgivet i: | J Clin Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7792623/ https://ncbi.nlm.nih.gov/pubmed/33374989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10010002 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|